S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)

Repligen (RGEN) Stock Forecast, Price & News

$160.21
-0.79 (-0.49%)
(As of 04:00 PM ET)
Compare
Today's Range
$157.17
$162.58
50-Day Range
$157.53
$176.51
52-Week Range
$134.64
$225.62
Volume
353,797 shs
Average Volume
559,413 shs
Market Capitalization
$8.93 billion
P/E Ratio
66.20
Dividend Yield
N/A
Price Target
$199.00

Repligen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
24.2% Upside
$199.00 Price Target
Short Interest
Bearish
10.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
0.93mentions of Repligen in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$145,673 Sold Last Quarter
Proj. Earnings Growth
36.00%
From $1.75 to $2.38 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

220th out of 975 stocks

Biological Products, Except Diagnostic Industry

30th out of 162 stocks


RGEN stock logo

About Repligen (NASDAQ:RGEN) Stock

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

RGEN Price History

RGEN Stock News Headlines

Repligen (RGEN) to Acquire Fluid Management Company Metenova
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Waltham's Repligen to acquire Swedish firm
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
What 6 Analyst Ratings Have To Say About Repligen
Reasons For the Decline of Repligen Corporation (RGEN)
Repligen (RGEN) Receives a Buy from RBC Capital
Repligen (RGEN) Q2 Earnings Surpass Estimates
See More Headlines
Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

RGEN Company Calendar

Last Earnings
8/02/2023
Today
9/28/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RGEN
CUSIP
75991610
Employees
2,025
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$199.00
High Stock Price Forecast
$240.00
Low Stock Price Forecast
$165.00
Forecasted Upside/Downside
+24.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$185.96 million
Pretax Margin
22.17%

Debt

Sales & Book Value

Annual Sales
$801.54 million
Cash Flow
$4.39 per share
Book Value
$34.41 per share

Miscellaneous

Free Float
55,143,000
Market Cap
$8.94 billion
Optionable
Optionable
Beta
1.00

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Anthony J. HuntMr. Anthony J. Hunt (Age 59)
    Pres, CEO & Director
    Comp: $1.59M
  • Mr. Jon K. SnodgresMr. Jon K. Snodgres (Age 57)
    Chief Financial Officer
    Comp: $838.89k
  • Mr. James R. BylundMr. James R. Bylund (Age 59)
    Chief Operating Officer
    Comp: $820.26k
  • Ms. Christine  GebskiMs. Christine Gebski (Age 54)
    Sr. VP of Filtration & Chromatography
    Comp: $625.76k
  • Mr. Ralf  KuriyelMr. Ralf Kuriyel (Age 64)
    Sr. VP of R&D
    Comp: $661.75k
  • Mr. Keith Lee Robinson
    Chief Information Officer
  • Ms. Sondra S. Newman
    Global Head of Investor Relations
  • Ms. Kimberly A. Cornwell
    Gen. Counsel
  • Dr. Jaime M. Humara Ph.D.
    Sr. VP of Marketing
  • Mr. Neil Whitfield
    VP of Sales













RGEN Stock - Frequently Asked Questions

Should I buy or sell Repligen stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGEN shares.
View RGEN analyst ratings
or view top-rated stocks.

What is Repligen's stock price forecast for 2023?

9 brokers have issued 12-month price objectives for Repligen's shares. Their RGEN share price forecasts range from $165.00 to $240.00. On average, they expect the company's stock price to reach $199.00 in the next twelve months. This suggests a possible upside of 24.1% from the stock's current price.
View analysts price targets for RGEN
or view top-rated stocks among Wall Street analysts.

How have RGEN shares performed in 2023?

Repligen's stock was trading at $169.31 at the beginning of the year. Since then, RGEN stock has decreased by 5.3% and is now trading at $160.31.
View the best growth stocks for 2023 here
.

When is Repligen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our RGEN earnings forecast
.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) announced its earnings results on Wednesday, August, 2nd. The biotechnology company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.04. The biotechnology company earned $159.20 million during the quarter, compared to analyst estimates of $165.93 million. Repligen had a net margin of 18.92% and a trailing twelve-month return on equity of 7.83%. Repligen's revenue for the quarter was down 23.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.91 EPS.

What guidance has Repligen issued on next quarter's earnings?

Repligen issued an update on its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of $1.72-$1.80 for the period, compared to the consensus earnings per share estimate of $2.29. The company issued revenue guidance of $635.00 million-$665.00 million, compared to the consensus revenue estimate of $721.07 million.

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Who are Repligen's major shareholders?

Repligen's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (2.96%), Sands Capital Management LLC (2.86%), Brown Capital Management LLC (2.59%), Artisan Partners Limited Partnership (2.51%), Bank of New York Mellon Corp (1.90%) and Impax Asset Management Group plc (1.82%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends
.

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $160.31.

How much money does Repligen make?

Repligen (NASDAQ:RGEN) has a market capitalization of $8.94 billion and generates $801.54 million in revenue each year. The biotechnology company earns $185.96 million in net income (profit) each year or $2.42 on an earnings per share basis.

How many employees does Repligen have?

The company employs 2,025 workers across the globe.

Does Repligen have any subsidiaries?
The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.
Read More
How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for the company is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115.

This page (NASDAQ:RGEN) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -